0001181431-13-046845.txt : 20130828 0001181431-13-046845.hdr.sgml : 20130828 20130828200115 ACCESSION NUMBER: 0001181431-13-046845 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130826 FILED AS OF DATE: 20130828 DATE AS OF CHANGE: 20130828 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO BIOSCIENCES INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANDO DALE G CENTRAL INDEX KEY: 0001202278 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 131067089 MAIL ADDRESS: STREET 1: C/O CELL GENESYS INC STREET 2: 500 FORBES BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 rrd389332.xml FORM 4 X0306 4 2013-08-26 0 0001001233 SANGAMO BIOSCIENCES INC SGMO 0001202278 ANDO DALE G C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD RICHMOND CA 94804 0 1 0 0 VP, Therapeutic Dev. & CMO Common Stock 2013-08-26 4 M 0 10000 3.61 A 96798 D Common Stock 2013-08-26 4 M 0 1000 3.45 A 97798 D Common Stock 2013-08-26 4 S 0 11000 10.0412 D 86798 D Common Stock 2013-08-26 4 M 0 2000 5.19 A 88798 D Common Stock 2013-08-26 4 S 0 2000 10.0383 D 86798 D Common Stock 2013-08-26 4 S 0 2000 10.0383 D 84798 D Employee Stock Option (Right to Buy) 3.61 2013-08-26 4 M 0 10000 0.00 D 2014-08-01 Common Stock 10000 30000 D Employee Stock Option (Right to Buy) 3.45 2013-08-26 4 M 0 1000 0.00 D 2018-12-09 Common Stock 1000 198000 D Employee Stock Option (Right to Buy) 5.19 2013-08-26 4 M 0 2000 0.00 D 2014-12-19 Common Stock 2000 21000 D The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2013. Includes 50,000 shares and 35,000 shares subject to restricted stock units granted on December 8, 2011 and December 6, 2012, respectively, which will be issued as such units vest in accordance with their terms. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.13, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.135, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.135, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. All shares underlying this option are vested and immediately exercisable. /s/ Florence Tam, attorney-in-fact 2013-08-28